Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Bullboard - Stock Discussion Forum StageZero Life Sciences Ltd T.SZLS

Alternate Symbol(s):  SZLSF

StageZero Life Sciences, Ltd. is a Canada-based vertically integrated healthcare company. The Company is focused on improving the early detection and management of cancer and other chronic diseases through diagnostics telehealth programs. Its lead product, Aristotle, is a mRNA multi-cancer panel for simultaneously screening for multiple cancers from a single sample of blood with high... see more

TSX:SZLS - Post Discussion

View:
Post by brad129 on Mar 18, 2022 2:29pm

Care sales

Where did we get the numbers for Care that prior to acquisition they were doing 1 million per quarter? If correct than we should see minimum 1 million on the books since we have had a full quarter of sales.
Comment by Pacman28 on Mar 18, 2022 3:08pm
correct
Comment by TrippinAgain123 on Mar 18, 2022 3:57pm
This post has been removed in accordance with Community Policy
Comment by TrippinAgain123 on Mar 18, 2022 4:00pm
This post has been removed in accordance with Community Policy
Comment by LithLover on Mar 18, 2022 3:58pm
From the News release of Aug 16, 2021: TORONTO, ON / ACCESSWIRE / August 16, 2021 / StageZero Life Sciences, Ltd (TSX:SZLS)(OTC PINK:SZLSF) ("StageZero" or the "Company"), a healthcare company working to reduce the risk of cancer and other chronic diseases through early detection and intervention, today announced the signing of a share purchase agreement (the " ...more  
Comment by Skrit37 on Mar 18, 2022 4:08pm
Well done lithlover, you make it to easy for those who don't like homework haha
Comment by brad129 on Mar 18, 2022 4:09pm
Thanks Lithlover, I knew it came in an official NR, so that should be the baseline to start with and up from there. Based on the Hype of 10,000 existing patients and family members we better see greater than 2 million for the quarter, do you or anyone think that is an unreasonable expectation?
Comment by Liked2Think on Mar 18, 2022 4:11pm
$525K
Comment by Skrit37 on Mar 18, 2022 4:12pm
Yes ....unreasonable only because those #s of potential patients came from the horses mouth... Once we get a new horse, then we can start believing what we are told...until then all we have is finiancials every quarter, to back it up
Comment by LithLover on Mar 18, 2022 4:51pm
So if they continue at the same rate for Care and post another $1 million in Q4 that brings them to $4.5 million for the year in total revenue.  Say for simple math (and for Liked2think's benefit) that Covid and Aristotle were only $500,000 that's $5 million total revenue for 2021.   So these would be the YTD revenue numbers for the last 5 years.   2021 $5-5.5 ...more  
Comment by gojotv! on Mar 18, 2022 8:57pm
Haha, LithLover, stop it! You're confusing our idiot, braying 24/7 bashers with math, and knowledge... All things their concave little heads can't understand, lol. Long and strong SZLS. It easy doubled a few months ago, and stands to easy triple (or more) by summer's end! GLTA!
Comment by IainCaimbeul on Mar 18, 2022 9:36pm
We are saved at last, the mighty gojotv has spoken in double and triple tongues. Unfortunately he has no grasp of reality. God bless and save us from any offspring of the mighty gojo. He is very happy now that his mentor is baaaaaaack.
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities